^{Availability in HMOs, Inclusion in the NHB, Home Delivery service -“Brukinsa at Your Door}

BRUKINSA® is indicated for the treatment of adult patients with Waldenstrom’s macroglobulinemia (WM).

BRUKINSA® is indicated for the treatment of adult patients with Mantle cell lymphoma (MCL) who have received at least one prior therapy.

BRUKINSA® is indicated for the treatment of adult patients with Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

BRUKINSA® is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

For full details please refer to the Israeli PI as approved by the MoH.

MINJUVI® is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). For full details please refer to the Israeli PI as approved by the MoH.

MINJUVI® and the “triangle” design are registered trademarks of Incyte.

Poteligeo® is indicated for the treatment of adult patients with Mycosis Fungoides (MF) or Sézary Syndrom (SS) who have received at least one prior systemic treatment.
For full details please refer to the PI as approved by the IL MoH.